PRME
Prime Medicine, Inc.
$2.97
+0.02
(+0.68%)
Mkt Cap
536.43M
Volume
2,208,100
52W Range
1.18-6.94
Sector
Healthcare
Beta
2.36
EPS (TTM)
-1.27
P/E Ratio
-2.57
Revenue (TTM)
4.03M
Rev Growth (5Y)
-2.3%
EPS Growth (5Y)
N/A
Company Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.63M | 2.98M | 0 | 0 | 0 | 5.21M | 0 |
| Net Income | (201.14M) | (195.88M) | (198.13M) | (121.82M) | (165.37M) | (3.41M) | (2.53M) |
| EPS | -1.35 | -1.65 | -2.18 | -1.46 | -1.92 | -0.05 | -0.03 |
| Free Cash Flow | (167.09M) | (130.16M) | (174.14M) | (147.92M) | (38.23M) | (6.18M) | (1.33M) |
| FCF / Share | -1.12 | -1.10 | -1.91 | -1.52 | -0.40 | -0.06 | -0.01 |
| Operating CF | (162.56M) | (122.86M) | (165.41M) | (131.83M) | (34.08M) | (5.54M) | (1.33M) |
| Total Assets | 342.73M | 297.51M | 193.85M | 360.31M | 301.86M | 54.78M | 8.70M |
| Total Debt | 116.43M | 40.79M | 13.63M | 28.75M | 10.41M | 0 | 0 |
| Cash & Equiv | 63.03M | 182.48M | 41.57M | 187.62M | 185.42M | 36.98M | 8.65M |
| Book Value | 120.87M | 153.15M | 133.07M | 316.27M | 239.56M | 33.47M | 1.39M |
| Return on Equity | -1.66 | -1.28 | -1.49 | -0.39 | -0.69 | -0.10 | -1.82 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 856,000 | 838,000 | 1.23M | 1.11M | 1.45M | 2.18M | 209,000 | 0 | 591,000 | 0 | 0 | 0 |
| Net Income | (49.12M) | (46.08M) | (50.58M) | (52.59M) | (51.89M) | (42.28M) | (52.52M) | (55.33M) | (45.76M) | (65.64M) | (50.71M) | (42.38M) |
| EPS | -0.28 | -0.26 | -0.32 | -0.41 | -0.40 | -0.36 | -0.44 | -0.46 | -0.44 | -0.67 | -0.55 | -0.47 |
| Free Cash Flow | (42.92M) | (37.55M) | (35.29M) | (42.98M) | (51.28M) | 14.45M | (27.19M) | (47.39M) | (70.03M) | (45.70M) | (42.08M) | (42.80M) |
| FCF / Share | -0.24 | -0.25 | -0.22 | -0.33 | -0.39 | 0.12 | -0.23 | -0.40 | -0.67 | -0.47 | -0.46 | -0.47 |
| Operating CF | (42.71M) | (37.26M) | (35.04M) | (41.41M) | (48.86M) | 16.25M | (25.91M) | (45.49M) | (67.71M) | (43.86M) | (39.17M) | (40.82M) |
| Total Assets | 294.73M | 342.73M | 385.01M | 279.01M | 328.16M | 297.51M | 332.78M | 259.70M | 311.38M | 193.85M | 239.15M | 280.87M |
| Total Debt | 114.51M | 116.43M | 118.14M | 119.74M | 121.15M | 40.79M | 41.25M | 41.58M | 43.79M | 13.63M | 17.04M | 25.44M |
| Cash & Equiv | 64.11M | 63.03M | 71.40M | 53.80M | 91.88M | 182.48M | 117.98M | 55.60M | 94.16M | 41.57M | 43.96M | 120.58M |
| Book Value | 76.70M | 120.87M | 161.82M | 60.86M | 106.92M | 153.15M | 189.50M | 196.59M | 243.77M | 133.07M | 193.96M | 240.10M |
| Return on Equity | -0.64 | -0.38 | -0.31 | -0.86 | -0.49 | -0.28 | -0.28 | -0.28 | -0.19 | -0.49 | -0.26 | -0.18 |
PRME News
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)
Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)
Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis